An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing

NCT07141771 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

SCLC, Extensive Stage

Interventions

DRUG: Serplulimab
DRUG: Fluzoparib
DRUG: Topotecan/Irinotecan/Paclitaxel/Temozolomide
DRUG: Etoposide/Carboplatin/Cisplatin
DRUG: Lurbinectedin
DRUG: Temozolomide

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences